Esperion Therapeutics to Provide Second Quarter Program Updates and Financial Results by longitudeadmin | Jul 29, 2015 | Portfolio News
Esperion Therapeutics Announces Positive Top-Line Phase 2 Results for ETC-1002 in Patients With Hypercholesterolemia and Hypertension by longitudeadmin | Jul 28, 2015 | Portfolio News
Esperion Therapeutics Announces Removal of 240 mg Partial Clinical Hold for ETC-1002 by longitudeadmin | Jul 17, 2015 | Portfolio News
Rapid Micro Biosystems Completes $19 Million Senior Credit Facilities by longitudeadmin | Jul 8, 2015 | Portfolio News
